These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11306154)

  • 21. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
    ; Yeni P; Cooper DA; Aboulker JP; Babiker AG; Carey D; Darbyshire JH; Floridia M; Girard PM; Goodall RL; Hooker MH; Mijch A; Meiffredy V; Salzberger B
    Lancet; 2006 Jul; 368(9532):287-98. PubMed ID: 16860698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.
    MacArthur RD; Chen L; Peng G; Novak RM; van den Berg-Wolf M; Kozal M; Besch L; Yurik T; Schmetter B; Henley C; Dehlinger M;
    HIV Clin Trials; 2004; 5(6):361-70. PubMed ID: 15682349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
    Robbins GK; De Gruttola V; Shafer RW; Smeaton LM; Snyder SW; Pettinelli C; Dubé MP; Fischl MA; Pollard RB; Delapenha R; Gedeon L; van der Horst C; Murphy RL; Becker MI; D'Aquila RT; Vella S; Merigan TC; Hirsch MS;
    N Engl J Med; 2003 Dec; 349(24):2293-303. PubMed ID: 14668455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.
    Shlay JC; Sharma S; Peng G; Gibert CL; Grunfeld C
    J Acquir Immune Defic Syndr; 2008 May; 48(1):53-62. PubMed ID: 18491421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
    Gulick R
    AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
    Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
    Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
    Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
    Fisher M
    AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).
    Pollard RB; Tierney C; Havlir D; Tebas P; Fox L; Smeaton L; Richman D; Friedland GH
    AIDS Res Hum Retroviruses; 2002 Jul; 18(10):699-704. PubMed ID: 12167276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
    Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
    AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
    Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
    J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).
    Saag MS; Tebas P; Sension M; Conant M; Myers R; Chapman SK; Anderson R; Clendeninn N;
    AIDS; 2001 Oct; 15(15):1971-8. PubMed ID: 11600825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
    Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).
    Pérez-Molina JA; Serrano O; Milinkovic A; Domingo P; Currán A; Knobel H; Gaspar G; Rodrigo A; Jiménez-Expósito MJ; Hernández-Novoa B; Moreno S; The NUCREST Study
    HIV Clin Trials; 2010; 11(5):294-302. PubMed ID: 21126959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.